Search

everythinglearnresearchcommunity

for

Search:↓

Using Cyproterone Acetate with Eflornithine together is safe and works better for treating facial hair in women.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.

Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.

Both VEPA and ML-Y1 treatments are not effective enough for elderly non-Hodgkin's lymphoma patients.

The trial is testing if a helmet that uses light can prevent hair loss during chemotherapy.

Pentoxifylline is a safe and effective alternative to triamcinolone acetonide for treating localized alopecia areata.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

"Alpenta" effectively reduces hair loss and improves hair growth in women with telogen effluvium.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.

Second-generation antipsychotics offer no significant benefit over first-generation ones for schizophrenia.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Extracellular vesicles are important for disease treatment and monitoring.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Care for gender-dysphoric Veterans can be improved with a consistent, team-based approach.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

AVT is highly conserved and may have antimicrobial properties.

Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.